The FDA on December 21, 2017 granted regular approval to SIKLOSĀ® to reduce the frequency of painful crises and the need for blood transfusions in pediatric patients from 2 years of age and older with sickle cell anemia with recurrent moderate to severe painful crises. SIKLOSĀ® is a product of Addmedica.